Proteomics

Dataset Information

0

Kinome profiling of HRAS Q61K mutant SMS-CTR rhabdomyosarcoma cell line treated with tipifarnib

ABSTRACT: Hyperactive RAS signaling drives tumorigenesis in PAX 3/7::FOXO1 fusion-negative rhabdomyosarcoma (FN-RMS). Despite the frequency of these mutations, RAS pathway-directed therapies have been ineffective for RAS-driven RMS. Farnesyltransferase (FTase) inhibitors (FTIs), such as tipifarnib, inhibit HRAS membrane localization and blunt HRAS effector signaling, leading to an antitumor effect in HRAS-mutant FN-RMS preclinical models. Response to FTI is limited by adaptive feedback reactivation of ERK signaling and upregulation of wild-type (WT) RAS. We found that the combination of HRAS suppression with FTI and MEK inhibition (MEKi) impaired ERK reactivation and reduced ERK transcriptional output in HRAS-mutant RMS models. Co-targeting FTase and MEK restrained tumor progression and induced terminal myogenic differentiation. These findings highlight an effective combinatorial strategy and support its preclinical translation for patients with HRAS-mutant RMS. Here, kinome profiling was performed on the SMS-CTR(HRAS Q61K) RMS cell line after 24 or 48 hour exposure to 100 nM tipifarnib.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Steven Angus  

LAB HEAD: Christine Pratilas

PROVIDER: PXD062989 | Pride | 2026-02-12

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
2024_05_139_Exploris_25cmES_AngusSample10_6uL.raw Raw
2024_05_139_Exploris_25cmES_AngusSample11_6uL.raw Raw
2024_05_139_Exploris_25cmES_AngusSample12_6uL.raw Raw
2024_05_139_Exploris_25cmES_AngusSample1_6uL.raw Raw
2024_05_139_Exploris_25cmES_AngusSample2_6uL.raw Raw
Items per page:
1 - 5 of 26
altmetric image

Publications

Hyperactive RAS signaling, induced by mutations in NRAS, HRAS, or KRAS, drives tumorigenesis in most PAX3/7::FOXO1 fusion-negative rhabdomyosarcomas (FN-RMS). Despite the frequency of these mutations, indirect RAS pathway-directed therapies have been ineffective for RAS-driven RMS. Farnesyltransferase (FTase) inhibitors (FTIs), such as tipifarnib, inhibit HRAS membrane localization and blunt RAS effector signaling, leading to an antitumor effect in HRAS-mutant FN-RMS preclinical models. However,  ...[more]

Similar Datasets

Transcriptomics Combined inhibition of HRAS and MEK induces tumor regression and restores myogenic differentiation in HRAS-mutant rhabdomyosarcoma
2025-12-08 | GSE312030 | GEO
Genomics Liaison between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion-Negative Rhabdomyosarcoma
2019-12-25 | GSE137168 | GEO
Proteomics Kinome profiling of patient JMML samples pre- and post-trametinib treatment
2024-04-23 | PXD042328 | Pride
Transcriptomics A MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting [RNA-seq]
2023-08-30 | GSE241282 | GEO
Genomics A MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting [ChIP-seq]
2023-08-30 | GSE241279 | GEO
Genomics A MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting [Hi-ChIP]
2023-10-16 | GSE245495 | GEO
Transcriptomics Transcriptome analysis of genetically engineered murine fusion-negative rhabdomyosarcoma model-derived cell lines
2021-05-31 | GSE175816 | GEO
Transcriptomics Differences in gene expression between ASP WT and ASPcKO tumors
2021-08-24 | GSE166809 | GEO
Transcriptomics TWIST2-Mediated Chromatin Remodeling Promotes Fusion-Negative Rhabdomyosarcoma [RNA-seq FN-RMS Cells]
2023-03-20 | GSE207167 | GEO
Genomics TWIST2-Mediated Chromatin Remodeling Promotes Fusion-Negative Rhabdomyosarcoma [ChIP-seq]
2023-03-20 | GSE207165 | GEO